EPM
ACAD icon

Equitec Proprietary Markets’s Acadia Pharmaceuticals ACAD Stock Holding History

Equitec Proprietary Markets’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-5,500
Closed -$179K – 153
2015
Q1 		$179K Buy
+5,500
New +$189K 0.01% 108

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Equitec Proprietary Markets's ACAD Position: Q2 2015 in Review

Equitec Proprietary Markets sold out of Acadia Pharmaceuticals (ACAD) in Q2 2015, closing a stake of 5,500 shares — an estimated $179K sold.

Equitec Proprietary Markets first reported a position in ACAD in Q1 2015 and held it in 1 quarter. The position peaked at $179K in Q1 2015. 188 funds tracked by Wall St. Rank hold ACAD as of Q2 2015.

  • Equitec Proprietary Markets reported no remaining Acadia Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Equitec Proprietary Markets sold 5,500 Acadia Pharmaceuticals shares in Q2 2015, an estimated $179K.
  • Equitec Proprietary Markets first reported a position in Acadia Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Equitec Proprietary Markets's Acadia Pharmaceuticals position peaked at $179K in Q1 2015.
  • 188 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2015.

Based on Equitec Proprietary Markets's 13F filing for Q2 2015, filed 5 Aug 2015.